Journal article

A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program.

Malcolm S Reid, Burt Angrist, Sherryl A Baker, Siobhan O'leary, Jennifer Stone, Marion Schwartz, Deborah Leiderman, Ann Montgomery, Ahmed Elkashef, Dorota Majewska, James Robinson, John Rotrosen

Substance Abuse | Published : 2005

Abstract

A placebo controlled, double-blind trial of mecamylamine treatment of cocaine dependence was performed in methadone or LAAM maintained subjects who met DSM-IV criteria for cocaine dependence. After an eight-week placebo run-in screening period, 35 subjects were randomly assigned to receive either mecamylamine (6 mg/day) or placebo transdermal patches for a 16-week treatment period. Outcome measures included quantitative urine benzoylecognine (BE) levels, self-report of cocaine use, cocaine craving, global impression scores, mood, retention, and safety. Mecamylamine was well tolerated, and study retention did not differ by treatment group. Evidence for cocaine use, based on urine BE levels an..

View full abstract